Accenture plans on ‘exiting’ staff who can’t be reskilled on AI amid restructuring strategy

Accenture plans on ‘exiting’ staff who can’t be reskilled on AI amid restructuring strategy


A logo sits illuminated at the Accenture booth in Mobile World Congress 2025 on March 03, 2025 in Barcelona, Spain.

Xavi Torrent | Getty Images News | Getty Images

Tech consultancy Accenture has laid out plans to lay off staff that aren’t able to reskill on artificial intelligence amid a broader restructuring strategy which will see the company prioritize AI efforts.

Accenture CEO Julie Sweet said in a call Thursday that as advanced AI becomes “a part of everything we do” and the global professional services company continues to invest significantly in the area, it expects employees to “retrain and retool” at scale.

“We are investing in upskilling our reinventors, which is our primary strategy,” Sweet said. She explained that the company is “exiting on a compression timeline” people for whom reskilling isn’t a “viable path.”

Sweet said Accenture had already reskilled 550,000 workers on the fundamentals of generative AI and outlined a six-month $865 million business optimization program, which detailed costs associated with severance and headcount reductions.

“We expect savings of over $1 billion from our business optimization program, which we expect that we will reinvest in our business and in our people because it’s so important for our future growth and so we expect to reinvest that while still delivering modest margin expansion,” Accenture Chief Financial Officer Angie Park said.

Alongside cuts, the company is continuing to hire and has beefed up its AI talent with 77,000 employed AI and data professionals in 2025, up from 40,000 in 2023. Sweet said its also expecting to increase the company’s headcount in the next financial year across markets including the U.S. and Europe.

“Our number-one strategy is upskilling, given the skills we need, and we’ve had a lot of experience in upskilling, we’re trying to, in a very compressed timeline, where we don’t have a viable path for skilling, sort of exiting people so we can get more of the skills in we need,” Sweet added.

The company reported revenues of $69.7 billion this year, a growth of 7% from the prior year. In an interview with CNBC’s “Squawk on the Street,” Sweet pinned this growth on massive client demand to deploy AI across organizations.

Accenture CEO Julie Sweet on earnings beat: Our early investment in AI is paying off

“Our early investment in AI is really paying off,” Sweet told CNBC. “We feel very good as we go into FY26 with the momentum we’re seeing in our business which is driven by accenture being the company that you really partner to make sure you can use advanced AI.”

“Every CEO, board and the C-suite recognize that advanced AI is critical to the future. The challenge right now they’re facing is that they’re really excited about the technology and they’re not yet AI ready for most companies,” she added.



Source

Supreme Court allows Trump to withhold  billion in foreign aid funding
World

Supreme Court allows Trump to withhold $4 billion in foreign aid funding

A person walks past the U.S. Supreme Court in Washington, D.C., U.S., April 21, 2025. Kevin Lamarque | Reuters The Supreme Court on Friday handed another win to the Trump administration by allowing it to withhold $4 billion in spending on foreign aid that was appropriated by Congress. A federal judge had previously ruled that the administration would have […]

Read More
Chinese stocks are on fire this year, drawing big interest from foreign and domestic investors
World

Chinese stocks are on fire this year, drawing big interest from foreign and domestic investors

When Hou Yujie isn’t convincing customers to rent traditional Chinese clothing for photos at the country’s famous Forbidden City, she and her friends are checking stocks. Hou recently put 10% of her money in the market. In just a few days, she earned one month’s salary — and she’s thrilled.  “Interest rates for bank deposits […]

Read More
U.S. pharma tariffs spare India’s generic drugmakers — but leave investors jittery
World

U.S. pharma tariffs spare India’s generic drugmakers — but leave investors jittery

MUMBAI, INDIA – MARCH 3: A technician works at a Cipla laboratory March 3, 2002 in Vikhrohi, Mumbai, India. Jean-marc Giboux | 3rd Party – Misc | Getty Images Stocks of leading Indian drugmakers fell on Friday, even though the 100% U.S. tariffs on branded and patented drug imports are unlikely to affect these companies. […]

Read More